title: Intracellular antibodies: development and therapeutic potential.
abstract: Single-chain antibodies, synthesized by the cell and targeted to a particular cellular compartment, can be used to interfere in a highly specific manner with cell growth and metabolism. Recent applications of this technology include the phenotypic knockout of growth-factor receptors, the functional inactivation of p21ras and the inhibition of HIV-1 replication. Intracellular antibodies are likely to have a widespread impact in biological research as a simple and effective alternative to other forms of gene inactivation; they demonstrate clear potential as reagents for cancer therapy and for the control of infectious diseases.
authors.affiliation: Division of Human Retrovirology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: J H
authors.initials: JH
authors.lastname: Richardson
authors.forename: W A
authors.initials: WA
authors.lastname: Marasco
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000906:Antibodies / Q000378:metabolism / Q000627:therapeutic use*; D001709:Biotechnology / Q000639:trends; D015195:Drug Design; D006801:Humans; D007424:Intracellular Fluid / Q000276:immunology; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000737:chemistry / Q000378:metabolism; D015513:Oncogene Proteins / Q000037:antagonists & inhibitors; D021382:Protein Sorting Signals; D017978:Receptors, Growth Factor / Q000378:metabolism; D014779:Virus Replication / Q000276:immunology
chemical_list: D000906:Antibodies; D009842:Oligopeptides; D015513:Oncogene Proteins; D021382:Protein Sorting Signals; D017978:Receptors, Growth Factor; C073762:lysyl-aspartyl-glutamyl-leucine